Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $1.59 million for the quarter.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.12. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $2.98 million. On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Autolus Therapeutics Trading Up 7.6 %
NASDAQ:AUTL opened at $1.41 on Thursday. Autolus Therapeutics has a 1 year low of $1.11 and a 1 year high of $5.00. The firm's fifty day simple moving average is $1.60 and its 200 day simple moving average is $2.41. The firm has a market capitalization of $375.19 million, a PE ratio of -1.17 and a beta of 2.06.
Analyst Upgrades and Downgrades
AUTL has been the topic of several research analyst reports. Truist Financial dropped their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Thursday, April 10th. Finally, Wells Fargo & Company cut their price target on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday, March 21st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $9.32.
Check Out Our Latest Stock Report on Autolus Therapeutics
Autolus Therapeutics Company Profile
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
